Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

To identify potential pharmacodynamic biomarkers to guide dose selection in clinical trials using anti-interferon-alpha (IFN-α) monoclonal antibody (mAb) therapy for systemic lupus erythematosus (SLE), we used an Affymetrix human genome array platform and identified 110 IFN-α/β-inducible transcripts...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yao, Yihong, Higgs, Brandon W., Morehouse, Chris, de los Reyes, Melissa, Trigona, Wendy, Brohawn, Philip, White, Wendy, Zhang, Jianliang, White, Barbara, Coyle, Anthony J., Kiener, Peter A., Jallal, Bahija
Format: Artigo
Idioma:Inglês
Publicat: SAGE-Hindawi Access to Research 2009
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2950308/
https://ncbi.nlm.nih.gov/pubmed/20948567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4061/2009/374312
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars